12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

biOasis preclinical data

In a mouse xenograft model of aggressive human breast carcinoma, twice-weekly subcutaneous BT2111 completely halted tumor growth vs. a 400% increase in tumor size for placebo (p=0.0058). BT2111 was...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >